Amgen Is Defensive in Some Selloffs, Not All of Them

Amgen's low market correlation can soften ordinary down days, but higher volatility and event risk mean the stock is not a simple defensive substitute for the S&P 500.
Amgen has often moved less than the market on ordinary down days, but its historical record does not make it a guaranteed defensive holding.
Trefis measured Amgen against the S&P 500 over daily market moves. When the index declined, the average S&P 500 loss was about 0.588%, while a hypothetical $10,000 Amgen position lost only $15.90 on average. On index up days, the same Amgen position gained roughly $42.40 while the market rose 0.638%.
Those averages reflect weak co-movement, not low standalone risk. Amgen's annualized volatility was about 29.4% in the sample, compared with 12.7% for the index, while estimated correlation was only 0.22 and market sensitivity was near 0.51. Company-specific drug data, regulatory decisions and earnings can produce large moves even when the broader market is calm.
March provides a useful counterexample. During a period when the index fell 5.1%, Amgen declined 9.4%. A defensive label based on average days would have failed during that episode. Investors therefore need to distinguish diversification from capital preservation: an asset can have low correlation and still experience a severe drawdown.
Over five years, Trefis calculates an annualized Amgen return of 19.4% versus 13.4% for the S&P 500. Volatility was also higher at 24.9% versus 17.1%, leaving return per unit of volatility almost identical, at 0.779 for Amgen and 0.784 for the index. These historical figures exclude investor-specific taxes and trading costs and do not predict future performance.
The business explains the mixed profile. Stable demand for medicines can provide resilience during economic weakness, but patent losses, biosimilar competition, clinical results and pricing policy create independent shocks. Prolia and Xgeva declines are a current example of risk that has little to do with the economic cycle.
Amgen may improve portfolio diversification because its drivers differ from the market's. It should not be treated like cash or a low-volatility bond proxy. Position size and exposure to biotechnology events matter more than the defensive label.
Continue your SPY research
Related News
NYSE Extends Options Trading, but Early Volume Shows the Limits
NYSE added premarket and post-close options sessions for 29 heavily traded stocks and funds. The launch answers demand for longer trading access, but thin initial volume highlights liquidity and execution risks.
Trump Media and Rumble Fell Faster Than the Market as Merger Risk Loomed
Trump Media dropped 6% and Rumble 8% during a broader selloff, highlighting their high volatility. For DJT, the pending TAE merger adds execution, dilution and fusion-development risk.
Carnival's Record 2027 Bookings Shift Attention to Pricing
Carnival reported record booked occupancy and pricing for 2027, supporting demand visibility after a strong share-price rebound. The next test is whether realized yields and costs preserve that advantage.
CoreWeave Credit Insurance Tops 1,000 Basis Points as Debt Fears Rise
CoreWeave's five-year credit-default swaps moved above 1,000 basis points while a 2031 bond yielded about 14.5%. Those market prices signal severe perceived credit risk even though the company continues to add long-term customer commitments.
Reddit's 61% Growth Supports Its Premium, but the Next Quarter Slows
Reddit's second-quarter revenue rose 61% and weekly active uniques reached 514.6 million, supporting a richer valuation than slower-growing peers. Management's third-quarter guide, however, implies a clear deceleration and leaves search traffic as a risk.
Disc Medicine's Phase 3 Win Clears the Clinical Bar, Not the FDA Bar
Bitopertin met both primary endpoints in Disc Medicine's pivotal APOLLO trial, strengthening its planned response to an earlier FDA rejection. The next value-driving step is regulatory acceptance, not another share-price reaction.










Latest comments